Loading
A phase 3 trial of Lazertinib in non-small-cell lung cancer and small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT05388669 by Janssen Research & Development, LLC, with 418 participants enrolled, started 2022-08-05 and due to reach its primary completion in 2024-01-03. Interventions recorded: Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
418 enrolled.
geometric CV 39.1%; Figures from the ClinicalTrials.gov results section (first posted 2026-02-02), not from a publication · geometric CV 41.5%
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady Stateprimary | Arm A: Lazertinib With Amivantamab SC-CF | 98 | 206 micrograms per milliliters (mcg/ml) | - | - | link |
| Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion | 98 | 144 micrograms per milliliters (mcg/ml) |
Shares Lazertinib, Johnson & Johnson, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Lazertinib, Johnson & Johnson, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Lazertinib, Johnson & Johnson, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Lazertinib, Johnson & Johnson, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Lazertinib, Johnson & Johnson, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Lazertinib, Johnson & Johnson, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Lazertinib, Johnson & Johnson, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.